Home / About us / Environmental, social and governance

Environmental, social and governance

Responsibility is built into how we operate, from the quality of our work to the impact we have beyond it.

ESG performance, unified around one standard: Quality

Our approach to environmental, social and governance performance follows the same principles that guide our quality systems: clear standards, measurable progress and continuous improvement.

We track performance through a structured ESG platform and hold recognized certifications across each area, giving you clear evidence of how we operate and the same rigor we apply to every study we support.

ISO-accredited systems

Our quality and environmental management systems are certified to ISO 9001 and ISO 14001, supporting consistent standards across our operations.

Silver EcoVadis rating

We hold a Silver EcoVadis rating (May 2026), providing an independent, third-party assessment of our sustainability performance.

Independent validation and assurance

Our systems undergo external IT and cyber resilience audits every 18 months, and we hold Cyber Essentials Plus certification for data security.

Reducing environmental impact through measurable action

Reducing our environmental footprint means reducing the impact our operations have on the environment, from the energy we use to the emissions and waste we generate.
We are working to reduce that footprint under a decarbonization plan aligned with our commitment to the Science Based Targets initiative.

Recent action includes moving our fleet from diesel to electric vehicles, with solar panel installation underway to increase our use of renewable energy. We report annually on energy use, emissions and waste and continue to strengthen sustainability across our supply chain.

Responsibility grounded in human impact

Our social commitments reflect the responsibility that comes with our work, our people and the communities around us.

Purpose
Our work starts with donated human tissue and a clear purpose: contributing to research that can change lives, while treating every donation with the responsibility and respect it deserves.

People
Our people make our work possible. We support an inclusive workplace where they can develop and thrive, backed by Real Living Wage accreditation and an annually audited health and safety policy.

Community
Our impact extends beyond our work. Global-facing and proudly rooted in the North East, we support our local community through sponsorship of Sunderland Rugby U13s, Belmont FC U15 Girls, North Shields U8 Reds Girls, Tynemouth Cricket Club and Cramlington Town Women.

How can our ESG commitments support your work?

Our ESG framework shapes how we operate, helping ensure reliable, responsible collaboration from the start.

Accountability built into how we operate

Our governance systems protect quality, data integrity and security while supporting ethical conduct and transparent reporting, including metrics such as gender pay balance.

  • Protecting data: We maintain GDPR-compliant data handling, hold Cyber Essentials Plus certification and undergo external IT and cyber resilience audits every 18 months, giving you confidence in how your data is managed and protected.
  • Clear accountability: Our ESG team includes a dedicated ESG coordinator, with clear reporting lines, policy ownership and regular review cycles. A whistleblowing policy protects employees who raise concerns, supporting an accountable and responsible culture.
  • Responsible partnerships: We use a supplier due diligence resource to assess new partners against our responsible supply-chain expectations, extending the standards we set for ourselves across the partners we work with.

Everything you need to verify

For further detail on our certifications and quality systems, visit our quality and compliance page or get in touch.

News

FibroFind appoints leading transplant physician Professor Andrew Fisher as Chief Medical Officer

FibroFind appoints Professor Andrew Fisher as Chief Medical Officer as the company continues its global expansion.

Poster

Combination of an Acetyl-Coenzyme A Carboxylase Inhibitor and Fibroblast Growth Factor-19 Reduced Tissue Triglyceride Content and Fibrosis in Human Precision-Cut Liver Slices

See how combining ACC inhibition with FGF19 reduced triglyceride accumulation and fibrosis in human precision-cut liver slices.

News

FibroFind appoints new CEO to lead firm through next phase of growth

FibroFind appoints co-founder Lee Borthwick as CEO to lead its next phase of growth and scale its human-relevant preclinical testing platform.

The evidence your program demands

Select a preclinical partner built for high-stakes decisions.